News
-
Semaglutide Meal Plan: A Simple Day Structure
A useful plan is flexible: smaller meals, protein early, fiber at a tolerable pace, and fluids across the day. This sample day uses portion ranges rather than a calorie rule.
-
Semax Half-Life: The Honest Answer Is Unknown
There is no measured Semax half-life in humans. Rat studies show that intact Semax reaches the brain within minutes and breaks down quickly, but they do not supply a reliable human clock.
-
Where to Inject CJC-1295 Ipamorelin: Site Guide
CJC-1295/ipamorelin is generally given into fatty tissue just under the skin. Common areas include the abdomen, thigh, back of the upper arm, and upper buttock, but the pharmacy label sets the sites for the exact prescription.
-
Compounded Semaglutide Side Effects: What Changes?
Most compounded semaglutide side effects come from semaglutide itself. Compounding can add separate risks involving concentration, added ingredients, ingredient form, sterility, and labeling.
-
Semaglutide Pronunciation: How to Say It
Semaglutide is pronounced sem-a-GLOO-tide. The middle is easier once you know where the stress goes and why several related medicine names share the same ending.
-
Kisspeptin Supplement: A Capsule Isn't the Peptide
A capsule sold as a kisspeptin supplement does not deliver the peptide used in the hormone and fertility studies people usually quote. Those studies used a vein or an injection under the skin, not an ordinary pill.
-
KLOW Peptide Before and After: An Honest Timeline
There is no clinical before-and-after timeline for KLOW because no published study has tested the finished blend. Here is what component studies measured over three days to 12 weeks—and why those clocks are not a promise.
-
PT-141 Half-Life Is About 2.7 Hours
The number is short, but it is not a stopwatch for how long someone feels an effect. Here is what the label's timing, clearance range, and safety limits actually mean.
-
Sermorelin and Alcohol: Can You Drink?
No human study has tested sermorelin and alcohol together. The concern is less a known toxic interaction than alcohol working against nighttime growth-hormone release, sleep, and IGF-1.
-
SS-31 Side Effects: What the Trials Found
SS-31 most often caused redness, itching, pain, or swelling where it was injected. Most reactions in trials were mild to moderate, but the label also warns about allergic reactions that can become serious.
-
TB-500 10 mg: What the Vial Size Really Means
A 10 mg mark states the total peptide mass the vial is meant to contain. It is not a per-injection dose, a concentration, or proof that an unverified vial contains what its label claims.
-
Tesamorelin vs Tirzepatide: Which Fits Which Goal?
Tesamorelin and tirzepatide can both change fat-related measures, but they answer different clinical questions. One has narrow evidence for deep abdominal fat in adults with HIV lipodystrophy; the other was studied for total body weight.
-
Is CJC-1295 Ipamorelin Safe? What We Know
Short human studies offer limited reassurance, but the blend itself has not been tested in a published trial and its long-term safety is unknown. A careful answer has to include both facts.
-
MK-677 vs Sermorelin: Why the Route Matters
MK-677 is an unapproved oral ghrelin mimic, while sermorelin is a prescribed GHRH peptide. Both can raise growth-hormone signals, but only one comes with a provider, pharmacy record and follow-up.
-
MOTS-c Before and After: What Research Shows
MOTS-c before and after photos are not clinical evidence. Human research has measured exercise and metabolic markers, but no completed study has published visible results from giving native MOTS-c—the exact peptide, not an altered analogue—to people.
-
PT-141 10mg Vial: What That Number Means
Ten milligrams describes what is in the whole vial. It does not tell you what to draw up, how many uses you have, or how a nasal product compares; those answers come from the prescription and pharmacy label.
-
Semaglutide Type 1 Diabetes: Guidance Has Limits
New 2026 guidance treats GLP-1 therapy as a possible obesity tool for some adults with type 1 diabetes, not as a replacement for insulin. The evidence is promising but small, and semaglutide is not approved to treat type 1 diabetes.
-
Sermorelin Half-Life: Minutes, Not Hours
Sermorelin leaves the bloodstream in minutes, but the growth-hormone pulse it starts can last for hours. Those are two different clocks, and neither is a personal dosing or drug-testing deadline.
-
Tirzepatide Meal Plan: Small Meals, Protein First
A useful tirzepatide meal plan is smaller and steadier: protein first, produce and fiber as tolerated, and fluids between meals. It should bend around appetite and side effects, not force a calorie target.
-
Where to Inject MOTS-c: What the Evidence Says
The available human trial records point to a subcutaneous shot into the fatty layer beneath the skin. The pharmacy label and prescriber—not an online injection map—set the site for a specific MOTS-c preparation.
Page 4 of 18 · 344 articles